Medicine & TechnologyScientists believe that monoclonal antibodies can help fight the coronavirus amidst the absence of the ultimate desired treatment, a viable vaccine. Learn what these antibodies are and how they work.
There's good news from Moderna's mRNA-1273 coronavirus vaccine candidate. A preliminary report states that all 45 volunteers in its clinical trial developed immunity to the coronavirus with no adverse reactions.
Scientists from Sechenov University said they have already finished human trials for a coronavirus vaccine and results have proven the medication's effectiveness. But there are no reports yet on its commercial reproduction.
For years, a horseshoe crab's blood has been used for developing new vaccines and medications. Experts are worried that the crab's population might be at risk due to numerous testings, particularly now with the coronavirus pandemic.
COVID-19 patients with severe cases often suffer from organ damage and sometimes death. But a team of scientists has proposed a novel way of limiting organ damage to improve outcomes for severe cases of the disease.
The United States has invested $42 million into producing syringes and needles in anticipation of the future coronavirus vaccine. The US President is hopeful that a vaccine could be ready by the end of the year or early next year.
According to Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, any coronavirus vaccine developed during this time would only give us "finite protection." Furthermore, he says that the first wave of the coronavirus is still far from over.
Tesla will be building mRNA microfactories for CureVac as the German company continues to develop its coronavirus vaccine Optimizing mRNA technology for two years, they are currently in their Phase I of clinical trials.
CanSino was the first biotech firm to complete successful human trials with a COVID-19 vaccine. They've continued to take the lead as they will soon begin Phase 3 with consistent promising efforts.
Professor Sarah Gilbert, who leads Oxford University's trial for its coronavirus vaccine candidate, says their jab could provide long-term immunity, which could last for several years. Furthermore, she says it could even give off antibodies three times more than a person who recovered from COVID-19.
A collaborative group of Japanese and foreign private and academic sectors is upgrading and expanding their coronavirus vaccine candidate's production. They aim to make the vaccine available for public use by next year's fall season. Click the link above to learn more.
The UK's second coronavirus vaccine candidate will go into human trials this week. According to researchers from Imperial College London, if deemed effective and safe, the vaccine would be made available to the public at a very affordable price.
The U.S. Army’s coronavirus vaccine contender was chosen to start human trials as early as this month. After giving off favorable results in mice studies, SpFN will be tried on humans to determine its safety and efficiency before being considered for public use.
Two studies involving testing experimental coronavirus vaccines in monkeys have shown promising results suggestive of immunity and protection against COVID-19. The researchers say that further studies need to be conducted to determine if the same results will be seen in human subjects.
Vaccine experts are skeptical of Moderna's vaccine candidate. On Monday, the company released information regarding their vaccine developing an immune response in their subjects. Other researchers, seemingly, have further questions to ask. Click the link above to read more.